Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks
📈 ARK Invest's Cathie Wood deployed approximately $19.1 million to purchase stakes in five beaten-down stocks, signaling confidence in long-term growth opportunities despite market volatility.
📱 Robinhood Markets (HOOD) received the largest investment, with ARK acquiring about 183,933 shares worth roughly $15.12 million.
🏦 This purchase increases Robinhood's weightage to 4.3% in the ARK Blockchain & Fintech Innovation ETF and 4.8% in the ARK Next Generation Internet ETF.
💡 Analysts see significant upside for HOOD, with average price targets implying a potential 63% gain from current levels to reach $125.65.
🎲 DraftKings (DKNG) saw an addition of approximately 58,048 shares valued around $1.48 million following its first positive net income in 2025.
📊 The online sports betting leader now holds 1.9% weightage in the ARK Blockchain & Fintech Innovation ETF and 1.05% in the ARK Next Generation Internet ETF.
🏥 Cerus Corp. (CERS) was acquired with about $1.37 million worth of shares, highlighting interest in healthcare innovation and pathogen reduction technology.
🧬 Compass Pathways (CMPS) received an investment of roughly $706,861 for 100,264 shares, focusing on psilocybin-based mental health treatments.
⚠️ Cerus is categorized as a risky penny stock that currently holds 1.2% weightage in the ARK Genomic Revolution ETF (ARKG).
🧠 Compass Pathways focuses on its investigational COMP360 therapy for treatment-resistant depression and PTSD during late-stage clinical trials.
📈 Wall Street analysts rate Robinhood as a "Moderate Buy" with potential upside reaching up to 133.5% at high price targets.
🚀 DraftKings receives a "Strong Buy" rating with analyst price targets suggesting the stock could surge by up to 110.7% over the next year.
⚕️ Cerus has made 20 million transfusible doses of INTERCEPT-treated blood components available to patients since the start of 2025.
🧠 Analysts see Compass Pathways as a "Strong Buy" with potential upside of 963.8% if it hits high price targets around $70.
🔄 ARK's strategy emphasizes investing in disruptive technologies and emerging disruptors even when market sentiment is uncertain.
- Cathie Wood's ARK Invest purchased approximately $19.1 million across five beaten-down stocks, demonstrating strong conviction in their long-term potential despite market volatility.
- Robinhood Markets (HOOD) now represents a significant 4.3% weightage in the ARK Blockchain & Fintech Innovation ETF and 4.8% in the ARK Next Generation Internet ETF, highlighting its strategic importance to ARK's portfolio.
- Analysts see potential upside of 63% for HOOD stock from current levels with a high price target of $180 implying a possible surge of up to 133.5% over the next year.
- Among analysts covering Robinhood, a majority provide bullish ratings with 15 giving it a 'Strong Buy' and 2 recommending a 'Moderate Buy'.
- DraftKings (DKNG) continues to benefit from state-by-state legalization across the U.S., expanding its total addressable market and improving profitability through disciplined marketing spending.
- In 2025, DraftKings reported positive net income for the first time driven by a 27% increase in revenue, signaling a strong turnaround in performance.
- Analysts see potential upside of 45% for DKNG stock with a high price target of $53 implying a possible surge of up to 110.7% over the next year.
- Among analysts covering DraftKings, a dominant majority provide 'Strong Buy' ratings with 25 out of 34 recommending this bullish stance.
- Cerus Corp. (CERS) has reached a milestone with 20 million transfusible doses of INTERCEPT-treated blood components made available to patients at the start of 2025.
- CERUS stock offers substantial upside potential with analysts projecting a 159% gain from current levels if it hits an average price target of $5.00.
- Compass Pathways (CMPS) is conducting many late-stage clinical trials for its investigational psilocybin-based therapy COMP360, which targets treatment-resistant depression and PTSD.
- Compass Pathways offers significant upside potential with analysts projecting a possible surge of up to 963.8% over the next year if the company meets its high price target of $70.
- Robinhood's stock is down 33% so far this year, indicating significant near-term weakness despite long-term potential.
- The company remains sensitive to trading volumes and crypto activity, making it a risky bet for investors amid market uncertainty.
- Robinhood currently holds 4.3% weightage in ARKF and 4.8% in ARKW, suggesting that any decline in these ETFs could amplify volatility.
- Cerus Corp. is classified as a risky penny stock, with analysts divided into two Strong Buy ratings and two Hold ratings among only four coverages.
- Compass Pathways faces uncertainty as it is conducting late-stage clinical trials for COMP360 that must succeed before regulatory approval can be obtained.
- Cerus reported minimal year-to-date performance of only a 2.03% decline, but its high-risk status as a small-cap healthcare company with limited analyst coverage increases valuation risk.
- Compass Pathways stock is up only 0.46% this year despite the high price target, suggesting potential lack of current market momentum compared to other growth stocks.
